Skip to main content

$0.005 (0.00%)

High

$0.01

Low

$0.00

Trades

68

Turnover

$72,477

Volume

14,697,042
30 June 2023 at 4:10pm
Register to track MXC and receive email alerts.

CimetrA anti-inflammatory pre-clinical study results

StockBot

416,823 posts

MXC released this announcement to the ASX on 27 June 2022, 11:27. The announcement is marked as price sensitive, and is 3 page(s) in length and 1.11MB in size.

You can view all announcements from MXC and see how they appear on a price chart on the announcements page.

At the date of this announcement, MXC was 0.026% short sold according to ASIC data. It was ranked the 598th most shorted stock on the ASX. It remains ranked 630th as of the latest reported data (02 April 2024).

Other Recent Announcements from MXC
Details of Company Address 30 June 2023, 17:34
Company Update 30 June 2023, 17:24
Results of Meeting 29 June 2023, 18:43
CimetrA anti-inflammatory pre-clinical study results 27 June 2022, 11:27
US Market Update - CimetrA Clinical Trial Progress 24 June 2022, 14:32
Glioblastoma pre-clinical trial results 16 June 2022, 15:30
Cognicann Clinical Trial Results 6 June 2022, 15:23
You must login or register to post a comment.

You must be logged in to post a reply.

Register to track MXC and receive email alerts.